Kolon Industries Partners with Three Billion to Develop Gene Therapy

Utilizing AI Innovation Technology... Promoting Various Synergies
Accelerating Discovery of New Candidate Substances for Gene Therapy

On the 2nd, Han Seong-su, Head of Future Technology Institute at Kolon Industries (left), and Geum Chang-won, CEO of Three Billion, signed a memorandum of understanding (MOU) for the development of gene therapy drugs at the Kolon One & Only Tower in Gangseo-gu, Seoul. Photo by Kolon Industries

[Asia Economy Reporter Choi Seoyoon] Kolon Industries Future Technology Institute announced on the 2nd that it has signed a Memorandum of Understanding (MOU) with 3billion, an AI-based rare disease genetic diagnosis company, to promote mutual exchange and cooperation related to gene therapy development.

Through this MOU, Kolon Industries Future Technology Institute and 3billion will pursue ▲data sharing and joint utilization of research information on genetic diseases ▲review of the possibility of joint research on R&D items ▲mutual exchange of professional personnel and academic information.

3billion is a company that provides genetic testing for over 7,000 types of genetic diseases based on AI technology and accumulated large-scale genetic data. It has a system capable of discovering new drug substances and predicting safety based on related big data and AI technology.

Going forward, both companies plan to discover candidate substances that can be used as new gene therapies and improve the efficiency of the discovery process to increase the success rate of therapeutic development.

Han Seongsu, head of Kolon Industries Future Technology Institute, said, “This agreement will be another growth engine in the bio healthcare field,” adding, “We expect synergy based on Kolon’s R&D competitiveness in gene therapy and 3billion’s AI technology.”

Kolon Industries Future Technology Institute will continue to actively engage in exchanges with various institutions to promote research and development in the bio healthcare field.

This content was produced with the assistance of AI translation services.